Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Thomas Karagiannis Ioannis Avgerinos Aris Liakos Stephano Del Prato David R Matthews Apostolos Tsapas Apostolos Tsapas

Published in: Diabetologia (2022)

and body weight, assessment of risk of bias solely for the primary outcome, and generalisation of findings mainly to individuals who are overweight or obese and already on metformin-based background therapy. PROSPERO registration no. CRD42021283449.

Keyphrases

body weight
type diabetes
weight loss
glycemic control
adipose tissue
metabolic syndrome
bariatric surgery
insulin resistance
cardiovascular disease
physical activity
weight gain
mesenchymal stem cells
replacement therapy